Sequent Scientific Ltd reported Q1 FY26 revenues of 4,414 million, up 13.1%; EBITDA increased by 24.7% to 602 million, and PAT rose by 93.7% to 176 million. The announcement also discussed the ongoing merger with Viyash Life Sciences, which is on track for completion in the coming months.